Rimegepant offers relief from migraine in phase 3 trial

  • Lipton RB & al.
  • N Engl J Med
  • 11 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Rimegepant, an investigational oral calcitonin gene-related peptide receptor antagonist, is safe and efficacious for treating migraine attacks.

Why this matters

  • Triptans have limited efficacy, adverse effects, safety concerns in patients with cardiovascular disease.

Key results

  • Compared with placebo group, rimegepant group more likely to be free at 2 hours from:
    • Pain (19.6% vs 12.0%; absolute difference, 7.6 percentage points; P<.001>
    • Most bothersome nonpain symptom (37.6% vs 25.2%; absolute difference, 12.4 percentage points; P<.001>
  • No difference in freedom from nausea at 2 hours (48.1% vs 43.3%; P=.21).
  • Leading adverse events with both rimegepant and placebo were nausea (1.8% vs 1.1%) and urinary tract infection (1.5% vs 1.1%).
  • Serious adverse events occurred in 0.2% of rimegepant group (back pain) and 0.4% of placebo group (chest pain, urinary tract infection).

Study design

  • Multicentre phase 3 randomised controlled trial among 1186 adults with ≥1-year history of migraine and 2-8 migraine attacks of moderate or severe intensity per month.
  • Randomisation: double-blind oral rimegepant vs placebo for single migraine attack.
  • Main outcomes: freedom from pain, freedom from most bothersome nonpain symptom at 2 hours after dose.
  • Funding: Biohaven Pharmaceuticals.

Limitations

  • Smaller, shorter-duration trial.
  • Lack of an active comparator.
  • Uncertain safety in patients having cardiovascular disease.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit